Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Strides Pharma Science Ltd - 532531 - Board to consider FY22 Results & Dividend on May 24, 2022

 Strides Pharma Science Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be heldon May 24, 2022 to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2022 and recommendation of dividend, if any, amongst other matters.Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company.
16-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations

 Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2022 ,inter alia, to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2022 and recommendation of dividend, if any, amongst other matters.
16-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Sub: Clarification on news item appeared online based on a report filed by Press Trust of India (PTI) titled 'Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs.' We refer to the above story that appeared online on May 14, 2022, and wish to submit that Stelis Biopharma Limited (Stelis), an associate of Strides Pharma Science Limited (Strides), has submitted its clarification to the Press Trust of India (PTI). A copy of the letter is attached for your reference. We request you to take the above on record.
15-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Compliance under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Chandulal Jamnadas Dattani
13-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Strides Pharma Science Ltd 2 CIN NO. L24230MH1990PLC057062 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2021-22, 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2020-21, 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Manjula RamamurthyDesignation :-Company Secretary Name of the Chief Financial Officer :- Badree Komandur Designation : -ED and CFO Date: 10/05/2022
10-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

 The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on May 09, 2022 for Pronomz Ventures LLP & Arunkumar Pillai
09-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 09, 2022 for Pronomz Ventures LLP & Arunkumar Pillai
09-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation regarding request received for Loss of Share Certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
06-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 We would like to inform you that the Company has completed the procedural requirements and dispatched the 'Letter of Confirmation' (LoC) vide Blue Dart courier on April 29, 2022 (POD No. 40473585703) as prescribed under SEBI Circular SEBI/ HO/ MIRSD/ MIRSD_RTAMB/ P/ CIR/ 2022/8 of January 25, 2022.
02-05-2022
Bigul

Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 02, 2022 for Pronomz Ventures LLP
02-05-2022
Next Page
Close

Let's Open Free Demat Account